GlassScriptPhysician profile
Ian Steele
NPI 1962584664
$2,249.90
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $314 · 2021: $397 · 2022: $793 · 2023: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $308.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $936.00 | 2019-2023 | Skyrizi, Humira, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.93 | 2019-2023 | Xifaxan |
| Pfizer INC. | $234.64 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $204.36 | 2019-2023 | Entyvio |
| Celgene Corporation | $142.29 | 2022-2023 | Zeposia |
| Vivus LLC | $88.50 | 2021-2022 | |
| Gilead Sciences, INC. | $79.07 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $66.31 | 2019-2022 | |
| Janssen Biotech, INC. | $44.69 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $42.19 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $23.95 | 2022 | |
| Shire North American Group INC | $22.69 | 2019 | |
| Genzyme Corporation | $21.94 | 2023 | |
| Intercept Pharmaceuticals, INC. | $18.32 | 2020 | |
| Ethicon US, LLC | $17.78 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.